RxDoctor Payments Data

Tonya Hudson

Family · Columbus, GANPI 1962476788

Payments from drug & device makers

$11,409in general payments, 2019–2025

Across 708 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • AstraZeneca$910
  • Bayer$731
  • GSK$627
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$11,30999%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,409 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$57,110
Medicare patients
242
Services billed
1,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide33$38,110
OzempicSemaglutide20$30,836
JardianceEmpagliflozin37$27,328
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$26,378
JanuviaSitagliptin Phosphate19$20,394
GlyxambiEmpagliflozin/Linagliptin14$18,130
LinzessLinaclotide16$15,820
KerendiaFinerenone17$15,557
FarxigaDapagliflozin Propanediol16$13,589
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$4,664
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,781
Albuterol Sulfate HfaAlbuterol Sulfate50$1,504
Atorvastatin Calcium216$1,459
Levothyroxine Sodium165$1,309
Valsartan57$1,295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi$384$45,45851 claims
Lilly USA, LLCMounjaro$1,220$38,11033 claims
Novo NordiskOzempic$1,528$30,83620 claims
GSKTrelegy Ellipta$627$26,37833 claims
MerckJanuvia$30$20,39419 claims
AstraZenecaFarxiga, Bevespi Aerosphere$910$18,25227 claims
AbbVieLinzess$1,215$15,82016 claims
BayerKerendia$731$15,55717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →